Cotranslational Translocation into the ER

Cotranslational translocation is the process by which a growing (nascent) polypeptide chain is threaded across, or inserted into, the endoplasmic reticulum membrane at the same time that the ribosome is still synthesizing it. This distinguishes ER import from post-translational import into mitochondria, chloroplasts, and peroxisomes, where a completed protein is captured after release from the ribosome. The distinguishing feature of the ER pathway is that targeting and translocation are mechanically coupled to translation itself: the ribosome pauses, physically relocates to the ER membrane, and docks onto a channel before elongation continues, so that the polypeptide never has time to fold up in the cytosol. The three-part machine that accomplishes this is: (1) the signal recognition particle (SRP), a cytosolic ribonucleoprotein that recognizes signal sequences as they emerge from the ribosome and transiently arrests elongation; (2) the SRP receptor (SR), a heterodimeric GTPase anchored in the ER membrane that captures the SRP–ribosome complex; and (3) the Sec61 translocon, a heterotrimeric protein-conducting channel that receives the ribosome, opens a pathway through (and sideways out of) the membrane, and threads the nascent chain across as translation resumes. A signal sequence — typically 15–30 residues with a hydrophobic core, often but not always at the extreme N-terminus — is the address code that triggers the whole cascade, exactly as introduced under sorting signals generally. The elegance of the system is that it solves a topological and thermodynamic problem simultaneously: how to move a polar, often large polypeptide across a hydrophobic lipid bilayer without ever exposing it, or the channel, to an energetically catastrophic aqueous pore in the membrane. The solution is a channel that behaves like a gated, laterally opening hourglass, allowing the same core machine to make secretory proteins (chain fully crosses into the lumen), type I/II/III membrane proteins (chain crosses partway and one or more segments exit sideways into the bilayer), and GPI-anchored proteins — all variations on one mechanism.

Step 1 — Signal sequence emergence and SRP capture. As a ribosome translating an mRNA extends the nascent chain, the first ~30–40 residues are protected inside the ribosomal exit tunnel. Once a hydrophobic signal sequence (or, for many membrane proteins, an internal transmembrane segment acting as a signal-anchor) emerges from the tunnel, it is bound by the SRP54 subunit of SRP, whose methionine-rich hydrophobic groove can accommodate the chemically diverse hydrophobic cores of different signal sequences. SRP is a complex of one 7SL RNA and six proteins (SRP9, 14, 19, 54, 68, 72 in mammals); the 9/14 heterodimer additionally causes translational (elongation) pausing or slowing, buying time for targeting before the whole protein is synthesized and possibly misfolded or mistargeted in the cytosol.

Step 2 — Targeting to the ER membrane. The SRP–ribosome–nascent chain complex diffuses to the ER membrane, where SRP54's GTPase domain engages the SRP receptor, a heterodimer of SRα (peripheral, GTPase) and SRβ (membrane-anchored, GTPase). Docking requires GTP bound to both SRP54 and SRα — a reciprocal GTPase pair that only fires efficiently when both partners are correctly loaded, providing a proofreading step against futile or premature docking.

Step 3 — Handoff to Sec61 and gated release. The ribosome is transferred from SRP to the Sec61 translocon (heterotrimeric Sec61α/β/γ in mammals, Sec61/Sbh1/Sss1 in yeast), which binds the large ribosomal subunit around its exit tunnel, aligning the tunnel with the translocon pore. This handoff triggers GTP hydrolysis in the SRP–SR complex, which releases SRP (recycled to the cytosol) and SR (recycled for another round), and — critically — is coupled to a GTPase exchange/proofreading step ensuring that the ribosome is not released into the translocon until it is properly seated, preventing loss of the nascent chain into the cytosol.

Step 4 — Channel opening and translocation. Sec61α forms an hourglass-shaped channel with a narrow constriction (the "pore ring," made of hydrophobic residues) partway through the membrane, capped on the lumenal side by a short helical "plug" domain. Insertion of the signal sequence into a lateral seam between transmembrane helices 2/3 and 7/8 of Sec61α displaces the plug and opens the channel. Translation resumes: each round of peptide bond formation pushes ~3 residues of nascent chain through the pore ring, which forms a flexible gasket around the passing chain rather than a rigid pore, maintaining a permeability seal.

Step 5 — Cleavage, folding, and completion. If the signal sequence is a cleavable N-terminal signal peptide, the ER-lumenal enzyme signal peptidase complex cleaves it, usually while the rest of the chain is still being translated, releasing the mature N-terminus into the lumen (or leaving it briefly in the membrane, for signal-anchor sequences that are not cleaved). Lumenal chaperones, principally BiP (an Hsp70 relative) bound to ATP, bind the emerging unfolded chain to prevent aggregation and to provide the pulling force ("ratchet" model) that keeps net movement of the chain into the lumen. For a fully secreted protein, translation terminates, the ribosome dissociates, and the completed protein is released into the lumen; for membrane proteins, one or more hydrophobic stretches exit laterally into the bilayer as transmembrane helices, and Sec61 then closes and can serve another ribosome.

The signal hypothesis and cell-free reconstitution (Blobel and colleagues, 1970s). Günter Blobel and David Sabatini first proposed, in 1971, that secreted proteins carry a signal within their sequence that directs them to the ER. The decisive proof came from cell-free translation-translocation assays. Blobel and Bernhard Dobberstein (1975) translated mRNA encoding a secretory protein (immunoglobulin light chain) in a wheat-germ or reticulocyte lysate lacking membranes. Without added microsomes (ER membrane vesicles), the protein was made as a slightly larger precursor. When rough microsomes were added during translation, the protein was translocated into the vesicle lumen, processed to its mature (shorter) size by a lumenal peptidase, and — crucially — protected from externally added protease (proteinase K), showing it was truly enclosed inside the vesicle and not merely stuck to its outside. Adding microsomes only after translation was complete failed to translocate the protein efficiently, showing that translocation normally requires the coupling to ongoing synthesis. This experiment simultaneously established: (1) a signal sequence exists and is cleaved, (2) translocation requires membrane components, and (3) translocation is temporally coupled to translation. Blobel received the Nobel Prize in Physiology or Medicine in 1999 largely for this body of work.

Discovery and reconstitution of SRP and SR (Walter, Blobel, and colleagues, 1980–1982). Peter Walter and Günter Blobel purified the cytosolic factor responsible for recognizing signal sequences and named it the signal recognition particle. They showed SRP does two things biochemically: it causes elongation arrest of ribosomes synthesizing a signal-sequence-containing chain in a cell-free system lacking membranes (measurable as a stall in polypeptide chain growth), and it can be released from this arrest specifically by microsomal membranes. Fractionating microsomal membrane proteins, they identified a membrane protein required to reverse SRP-mediated arrest and release the ribosome for translocation — the SRP receptor (originally called the "docking protein"). Reconstituting these purified components (ribosome, mRNA, SRP, SRP receptor, and a translocon-containing membrane) into a fully synthetic system that recapitulated translocation proved that this minimal set of components is sufficient, not merely correlated with, the targeting reaction.

Identification of the translocon: Sec61 genetics and photocrosslinking (Rapoport, Schekman, and colleagues, 1990s). Genetic screens in yeast by Randy Schekman's group identified sec61 mutants that blocked translocation of secretory proteins into the ER, and biochemical work by Tom Rapoport's group showed that a mammalian complex homologous to yeast Sec61 forms a ring around the nascent chain. Site-specific photocrosslinking experiments — engineering the nascent chain to carry a photoreactive amino acid at defined positions and then UV-irradiating translocation intermediates — showed that as the chain moves through the membrane, it crosslinks first to Sec61α and, when a hydrophobic transmembrane segment is present, transiently to lipid, directly demonstrating lateral exit of transmembrane domains from within the Sec61 channel into the bilayer. This provided direct physical evidence for the "lateral gate" model before any atomic structure existed.

Structural confirmation (Rapoport, Van den Berg, and colleagues, 2004 onward). The crystal structure of the archaeal SecY complex (the prokaryotic Sec61 homolog), solved by Van den Berg, Rapoport, and colleagues in 2004, revealed the hourglass shape, the hydrophobic pore ring, and the plug domain exactly as predicted from crosslinking data, and showed the lateral gate as a seam between two structural halves of the protein. Later cryo-electron microscopy structures of mammalian ribosome–Sec61 complexes and of the SRP–SR targeting complex (2010s) visualized the entire pathway at near-atomic resolution, confirming the GTPase-dependent handoff geometry predicted by decades of biochemistry. Structure and biochemistry converged on the same mechanism from two independent directions — a hallmark of a well-established model rather than an assumption.

Example 1 — Interpreting a protease-protection experiment. A researcher translates the mRNA for preprolactin (a secretory protein with a cleavable signal sequence) in a wheat-germ lysate. Four conditions are tested, and the resulting protein sizes/protease sensitivity are recorded.

Reasoning: Condition A shows that without membranes the chain is made at its full precursor length — proof a signal sequence is present but uncleaved in the cytosol. Condition B shows that co-translational membrane addition allows both translocation and cleavage by lumenal signal peptidase, shortening the product. Condition C is the critical control: if the protein were simply adsorbed to the outside of the vesicle, external protease would degrade it; because it survives, the protein must be inside the microsome, protected by the lipid bilayer. Condition D confirms this is a membrane-enclosure effect and not some protease-resistant fold, because solubilizing the membrane with detergent exposes the protein and it is degraded. This is essentially the logic of the original Blobel–Dobberstein experiments, and it is the standard way translocation is verified in a modern lab.

Example 2 — Signal sequence hydrophobicity and targeting efficiency (a quantitative scenario). Suppose a lab constructs three variant signal sequences for a reporter protein, differing only in the number of leucines within the 10-residue hydrophobic core (all else held constant), and measures the fraction of ribosomes that pause upon SRP binding (an assay for productive SRP engagement) in a cell-free system.

Reasoning: SRP54's signal-binding groove recognizes hydrophobicity, not a specific sequence motif, so reducing the number of hydrophobic residues in the core progressively weakens SRP binding affinity. Fewer SRP-arrested ribosomes (45% and 8% versus 85%) directly predicts a corresponding drop in productive translocation (30% and <5% versus 80%), because a chain that is never captured by SRP is released by the ribosome into the cytosol, where it usually misfolds or is degraded rather than reaching the ER. This mirrors real experiments (e.g., mutagenesis of the yeast prepro-α-factor or bacterial signal sequences) that established that the degree of hydrophobicity, not the exact identity of residues, is the key determinant of signal sequence function — a striking example of a "degenerate" sorting signal recognized by a physicochemical property rather than a strict consensus sequence, consistent with the general logic of Sorting Signals and Compartment Address Codes.

Günter Blobel (1936–2018) trained as a physician in Germany before emigrating to the United States, where he joined George Palade's laboratory at Rockefeller University — the same lineage of cell biologists who had used electron microscopy and subcellular fractionation to map the secretory pathway. Working with David Sabatini, Blobel proposed in 1971 that a protein's own sequence contains the information needed to direct it to the correct cellular compartment, the "signal hypothesis." He spent the following decades doggedly proving it experimentally, building cell-free systems that could be taken apart and reassembled component by component — mRNA, ribosomes, SRP, SRP receptor, microsomal membranes — until the entire targeting reaction could be reconstituted from purified parts. This reductionist, reconstitution-based style of experimentation became the template for how membrane trafficking is studied to this day, and it directly enabled the later work of Peter Walter, Randy Schekman, and Tom Rapoport that filled in the molecular identities of SRP, the SRP receptor, and the Sec61 translocon.

Medicine and disease. Mutations that weaken signal sequence recognition or Sec61 function cause identifiable human diseases: certain forms of diabetes insipidus result from vasopressin precursor signal-sequence mutations that impair ER targeting, and mutations in SEC61A1 cause a form of autosomal-dominant polycystic kidney disease and certain immunodeficiencies, because B cells and secretory epithelial cells are exquisitely sensitive to translocon efficiency. Alpha-1 antitrypsin deficiency and some forms of cystic fibrosis (CFTR misfolding) involve proteins that translocate but then fail downstream ER quality control, showing how translocation is the first checkpoint in a longer surveillance pathway (foreshadowing the The Secretory Pathway Overview).

Antibiotics and antifungals. Because bacterial and fungal signal-sequence-recognition and translocase machinery (SecYEG, the bacterial Sec61 homolog) differ enough from the human system, they are drug targets: natural product inhibitors that jam bacterial SecA/SecYEG selectively block bacterial secretion and cell-envelope biogenesis without touching the human ER translocon, offering a template for narrow-spectrum antibacterial development.

Cancer therapeutics. Small molecules that inhibit Sec61 (such as cotransin and its derivatives, and the natural product mycolactone) selectively block translocation of specific subsets of secretory and membrane client proteins, and are being explored as anticancer and immunomodulatory agents because they can suppress secretion of growth factors and cell-surface receptors implicated in tumor signaling.

Biotechnology. Recombinant protein production — insulin, monoclonal antibodies, vaccine antigens — in yeast, mammalian, or insect cell expression systems depends entirely on correctly engineered signal sequences to drive cotranslational translocation and secretion; optimizing signal peptide choice is a routine, economically important step in biopharmaceutical manufacturing, directly descended from the mechanistic understanding described here.

Basic cell biology and evolution. The Sec61/SecY channel is one of the most deeply conserved machines in life, found (with variations) in the ER of eukaryotes, the plasma membrane of bacteria, and the archaeal membrane, illustrating how a single ancient protein-conducting channel was repurposed across the tree of life for compartmentalized versus surface-directed protein export.

Ask the tutor: How does the Sec61 channel decide, in real time, whether a given hydrophobic segment should exit laterally into the membrane or stay inside the pore and keep threading toward the lumen?